Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2024 08:00 ET | Source: ArriVent BioPharma, Inc.

ArriVent BioPharma Reports First Quarter 2024 Financial Results

Presented preclinical firmonertinib (formerly furmonertinib) data at the 2024 American Association for Cancer Research (“AACR”) Annual MeetingDosed first patient in Phase 1b combination study of...
April 22, 2024 16:05 ET | Source: ArriVent BioPharma, Inc.

ArriVent Appoints Kristine Peterson to its Board of Directors

NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical...
March 28, 2024 16:05 ET | Source: ArriVent BioPharma, Inc.

ArriVent BioPharma Reports Full Year 2023 Financial Results

Company progresses the development of furmonertinib with a data readout planned for 2024Furmonertinib granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration Completed $201...
January 25, 2024 21:30 ET | Source: Arrivent Biopharma, Inc.

ArriVent Announces Pricing of Upsized Initial Public Offering

NEWTOWN SQUARE, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative...
January 05, 2024 16:15 ET | Source: Arrivent Biopharma, Inc.

ArriVent Appoints Winston Kung as Chief Financial Officer and Treasurer

NEWTON SQUARE, Pa., Jan. 05, 2024 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical...
October 30, 2023 06:00 ET | Source: Arrivent Biopharma, Inc.

ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib for First-Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

NEWTOWN SQUARE, Pa., Oct. 30, 2023 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical...
September 20, 2023 16:05 ET | Source: Arrivent Biopharma, Inc.

ArriVent Appoints Chris Nolet to its Board of Directors

NEWTOWN SQUARE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical...
September 10, 2023 01:30 ET | Source: Arrivent Biopharma, Inc.

Allist and ArriVent Announce Interim Results from Ongoing Phase 1b Trial with Furmonertinib at the 2023 World Conference on Lung Cancer

SHANGHAI, China, Sept. 10, 2023 (GLOBE NEWSWIRE) -- Allist Pharmaceuticals Co., Ltd. (“Allist”) and ArriVent Biopharma, Inc. (“ArriVent”) together announced that interim results from the Phase Ib,...